Allogene Therapeutics (ALLO) vs Contineum Therapeutics (CTNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Contineum Therapeutics (CTNM) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 11.8% versus a gain of 5.9%. Contineum Therapeutics is the larger company by market cap ($495.8 million vs $483.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | CTNM |
|---|---|---|
| Share price | $1.40 | $13.18 |
| Market cap | $483.69M | $495.85M |
| 1-day change | -2.10% | +3.53% |
| YTD return | +4.38% | +11.37% |
| 1-year return | +5.93% | +11.76% |
| 5-year return | -91.32% | — |
| EPS (TTM) | $-0.66 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $17.79 |
| 52-week low | $1.04 | $8.60 |
| Distance from 52-week high | -68.61% | -25.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +542.86% | +70.18% |
| Average volume | 5.65M | 502.82K |
| Shares outstanding | 345.49M | 32.96M |
| Employees | 150 | 51 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
ALLO vs CTNM FAQ
Which is bigger, Allogene Therapeutics or Contineum Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $495.85M compared with $483.69M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or CTNM?
CTNM returned +11.76% over the past 12 months, compared with +5.93% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Contineum Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Allogene Therapeutics and Biotechnology: Pharmaceutical Preparations for Contineum Therapeutics.